- Home
- BCDA vs EPIX Comparison
BCDA vs EPIX Comparison
Compare BCDA & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- EPIX
- Stock Information
- Founded
- BCDA N/A
- EPIX 2009
- Country
- BCDA United States
- EPIX Canada
- Employees
- BCDA N/A
- EPIX N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- EPIX Health Care
- Exchange
- BCDA Nasdaq
- EPIX Nasdaq
- Market Cap
- BCDA 11.3M
- EPIX 9.1M
- IPO Year
- BCDA N/A
- EPIX N/A
- Fundamental
- Price
- BCDA $1.56
- EPIX $0.20
- Analyst Decision
- BCDA Strong Buy
- EPIX Hold
- Analyst Count
- BCDA 1
- EPIX 3
- Target Price
- BCDA $25.00
- EPIX $2.00
- AVG Volume (30 Days)
- BCDA 46.4K
- EPIX 15.6M
- Earning Date
- BCDA 11-12-2025
- EPIX 08-13-2025
- Dividend Yield
- BCDA N/A
- EPIX N/A
- EPS Growth
- BCDA N/A
- EPIX N/A
- EPS
- BCDA N/A
- EPIX N/A
- Revenue
- BCDA N/A
- EPIX N/A
- Revenue This Year
- BCDA N/A
- EPIX N/A
- Revenue Next Year
- BCDA N/A
- EPIX N/A
- P/E Ratio
- BCDA N/A
- EPIX N/A
- Revenue Growth
- BCDA N/A
- EPIX N/A
- 52 Week Low
- BCDA $1.63
- EPIX $0.19
- 52 Week High
- BCDA $3.25
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- BCDA 30.27
- EPIX 7.82
- Support Level
- BCDA $2.11
- EPIX $0.19
- Resistance Level
- BCDA $2.29
- EPIX $0.21
- Average True Range (ATR)
- BCDA 0.12
- EPIX 0.02
- MACD
- BCDA -0.03
- EPIX 0.02
- Stochastic Oscillator
- BCDA 0.96
- EPIX 25.75
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.